Weekly Paclitaxel with or without AMG 386 for recurrent ovarian cancer
Conditions
Recurrent Ovarian Cancer
What is the purpose of this trial?
The purpose of this study is to evaluate whether AMG 386 in combination with paclitaxel improves the outcome of treatment, compared to treatment with paclitaxel alone. The study will be looking at these treatments in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancers who have previously received a platinum-containing regimen. AMG 386 is an investigational product that will be used in this study. AMG 386 is a man made medication designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Female
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Amgen, Inc
- Dates:
- November 2011
- Last Updated:
- Study HIC#:
- 1009007411
Clinicaltrials.gov ID: Yale3202892
